Androgens can play an important role in the progression of metastatic prostate cancer — simply defined as prostate cancer that spreads to other parts of the body.
In cases of metastatic castration-resistant prostate cancer (mCRPC), which is resistant to medical or surgical treatments that lower testosterone, tumors have shown the ability to produce their own androgen, which can help fuel their survival.1-4
The more you know about mCRPC after treatment with docetaxel, the better equipped you are to discuss treatment options with your doctor.
- Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res. 2008;68(11):4447-4454.
- Locke JA, Guns ES, Lubik AA, et al. Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer. Cancer Res. 2008;68(15):6407-6415.
- Stanbrough M, Bubley GJ, Ross K, et al. Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res. 2006;66(5):2815-2825.
- Titus MA, Schell MJ, Lih FB, Tomer KB, Mohler JL. Testosterone and dihydrotestosterone tissue levels in recurrent prostate cancer. Clin Cancer Res. 2005;11(13):4653-4657.